Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

M5353

Sigma-Aldrich

Mitomycin C

liquid, non-animal origin, suitable for cell culture, BioReagent

Synonym(s):

Ametycine, MMC, MitoExtra, Mitocin C, Mitomycin, Mitonco, Mitoplus, Mitozytrex, Mutamycin

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352207
NACRES:
NA.76

product name

Mitomycin C ready made solution, 10 mg/mL in DMSO, ≥98% (HPLC), Cell culture tested

Quality Level

Assay

≥98% (HPLC)

form

liquid

storage condition

protect from light

concentration

10 mg/mL in DMSO

storage temp.

−20°C

General description

Mitomycin C (MMC) produced by Streptomyces caespitosus is an anticancer antibiotic agent which inhibits proliferation of various cell types in vitro. MMC is DNA alkylating agent, that causes cross linking of complementary DNA strands resulting in: mutagenesis, inhibition of DNA synthesis, initiation of DNA repair events, and activation of apoptosis. Furthermore, MMC has an effect on ribosomal RNA leading to protein synthesis inhibition.
MMC is capable of inhibiting cell proliferation of human or murine embryonic fibroblast cells at concentration range of 0.2-20μg/mL. These treated cells are subsequently used as an adherent feeder layer in long-term culture assays mainly for growth of pluripotent stem cells. Feeder layer cells support the target cells by releasing growth factors to the cell culture and detoxification of the medium. Moreover, feeder layer cells play a role in ECM proteins synthesis that controls cell culture growth. In addition, feeder layer cells are used as a substrate for attachment of the target cells.
MMC also was used for BLC (basal-like cancer) cell line.
MMC as antibiotic agent showed a potent activity against MDR gram-negative bacteria like P. aeruginosa (2 μg/mL), E.Coli (0.5μg/mL) and A. baumannii (16μg/mL). MMC also has a strong activity against gram positive bacteria (0.2μg/mL).

Technical information
1.Mitomycin C ready made solution provides a safer alternative to the powder form by preventing hazardous particles exposure.
2.Please avoid repeated freeze thaw cycles of this product.
3.Mitomycin C solutions are light sensitive and should kept in the dark.
4.It is recommended to keep Mitomycin C solutions at pH 6-7.
5.The recommended concentration of Mitomycin C in cell culture assays is 0.2-20μg/mL. (Ref.8,9,12,13) Therefore, it is recommended to dilute the ready made solution 1:500-50,000.

Caution

Light sensitive

Physical form

Liquid - In DMSO

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

188.6 °F - closed cup

Flash Point(C)

87 °C - closed cup


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

FSL

Group 4: Flammable liquids
Type 3 petroleums
Hazardous rank III
Water insoluble liquid

JAN Code

M5353-5X0.2ML:
M5353-BULK:
M5353-VAR:
M5353-0.2ML:
M5353-0.2ML-PW:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L Ponchio et al.
Cytotherapy, 2(4), 281-286 (2002-06-04)
Mitomycin C (MMC), an antitumoral antibiotic, has been described inhibiting the proliferation of different cell types in vitro. Since irradiation is commonly used to stop the cell growth of adherent cells in several experimental models, we aimed to define the
Ronald Domalaon et al.
Frontiers in microbiology, 10, 1556-1556 (2019-07-30)
The lack of therapeutic options to treat infections caused by multidrug-resistant (MDR) pathogens, especially Gram-negative bacteria, is apparent. Therefore, it is imperative to develop new strategies to address the problem of antimicrobial resistance. Repurposing non-antibiotic commercial drugs for antimicrobial therapy
Sarah J Hill et al.
Molecular and cellular biology, 34(20), 3828-3842 (2014-08-06)
Sporadic basal-like cancers (BLCs) are a common subtype of breast cancer that share multiple biological properties with BRCA1-mutated breast tumors. Despite being BRCA1(+/+), sporadic BLCs are widely viewed as phenocopies of BRCA1-mutated breast cancers, because they are hypothesized to manifest

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service